Cardiovascular electronic implantable devices are an important and often necessary treatment for patients with symptomatic bradycardia, heart failure, and those at risk for recurrent ventricular arrhythmias. Two decades ago, seminal studies conclusively showed that cardiac resynchronization was an important treatment modality for patients with severe left ventricular dysfunction and conduction abnormalities.^1,2 However, it has consistently been noted that 20% to 30% of patients do not respond to therapy or appropriate therapy cannot be delivered because of limitations in venous anatomy, phrenic nerve stimulation, or the presence of scar.^1,2 The WiSE-CRT (Wireless Stimulation Endocardially for CRT) system is an innovative solution to these issues. First reported in the clinical literature a decade ago, the system uses acoustic energy transmitted to a small receiver electrode located in the endocardium that converts the acoustic energy into electrical energy to stimulate the ventricle.³ There are several potential advantages to this strategy since the receiver can be placed anywhere in the left ventricle to deliver more physiologic endocardial stimulation without anatomic constraint.